LRI Investments LLC Acquires 444 Shares of Zimmer Biomet Holdings, Inc. $ZBH

LRI Investments LLC lifted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 40.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,538 shares of the medical equipment provider’s stock after purchasing an additional 444 shares during the quarter. LRI Investments LLC’s holdings in Zimmer Biomet were worth $140,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Garde Capital Inc. bought a new position in Zimmer Biomet in the 1st quarter valued at about $29,000. Washington Trust Advisors Inc. bought a new position in Zimmer Biomet in the 1st quarter valued at about $30,000. Columbia River Financial Group LLC bought a new position in Zimmer Biomet in the 1st quarter valued at about $30,000. Accent Capital Management LLC bought a new position in Zimmer Biomet in the 1st quarter valued at about $35,000. Finally, Cullen Frost Bankers Inc. increased its holdings in Zimmer Biomet by 1,452.4% in the 1st quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 305 shares during the period. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Trading Down 2.6%

ZBH opened at $94.79 on Monday. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $114.72. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The company has a market cap of $18.78 billion, a P/E ratio of 23.06, a price-to-earnings-growth ratio of 2.18 and a beta of 0.67. The company has a fifty day moving average price of $101.31 and a two-hundred day moving average price of $98.15.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. During the same period in the previous year, the firm posted $2.01 earnings per share. The business’s revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s payout ratio is 23.36%.

Analysts Set New Price Targets

Several research firms have commented on ZBH. Raymond James Financial raised their target price on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Stifel Nicolaus raised their target price on shares of Zimmer Biomet from $115.00 to $118.00 and gave the company a “buy” rating in a report on Friday, September 19th. Evercore ISI decreased their target price on shares of Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a report on Tuesday, October 7th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday, October 8th. Finally, Redburn Partners set a $130.00 price target on shares of Zimmer Biomet in a report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $112.67.

Insiders Place Their Bets

In other news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the sale, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 1.39% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.